Characterization of naturally acquired multiple-drug resistance of Yoshida rat ascites hepatoma AH66 cell line

Anticancer Research

Volumn 16, Issue 3 A, 1996, Pages 1235-1240

  Miyamoto, Ken Ichi ^a   Wakabayashi, Dai ^a   Minamino, Tomoyoshi ^a,b   Nomura, Masaaki ^a   Wakusawa, Shinya ^a   Nakamura, Shigeo ^c  

^a HOKURIKU UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c Fuji Yakuhin Co Ltd   (Japan)

Author keywords

AH66; Glutathione; Multiple drug resistance; P glycoprotein; Rat ascites hepatoma; Topoisomerase

Indexed keywords

4 DIMETHYLAMINOAZOBENZENE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BUTHIONINE SULFOXIMINE; CHLORAMBUCIL; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ARTICLE; ASCITES HEPATOMA; CANCER CELL CULTURE; CANCER GRAFT; CELL MEMBRANE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; GLUTATHIONE METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; LIVER NEOPLASMS, EXPERIMENTAL; METALLOTHIONEIN; RATS; RATS, INBRED STRAINS; TUMOR CELLS, CULTURED;

EID: 0029900051     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ford JM and Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199,1990.
2. Borst P: Genetic mechanisms of drug resistance. Rev Oncol 4: 87-105, 1991.
3. Mattern J and Volm M: Multiple pathway drug resistance (Review) Int J Oncol 2: 557-561, 1993.
4. Yoshida T: Contributions of the ascites hepatoma to the concept of malignancy of cancer. Ann NY Acad Sci 63: 852-881, 1956.
5. Miyamoto K, Wakusawa S and Nakamura S: Drug resistance dependent on different molecular size P-glycoproteins in Yoshida rat ascites hepatoma cells. Biochem Pharmacol 3: 1143-1145, 1992.
6. Miyamoto K, Wakusawa S, Nakamura S, Tajima K and Hidaka H: Multidrug resistance in Yoshida rat ascites hepatoma cell lines. Anticancer Res, 12: 649-654, 1992.
7. Wakusawa S, Nakamura S, Inoko K and Miyamoto K: Sensitivity to antitumor drugs and vinblastine binding to membrane in rat ascites hepatorna AH66 cells Chem Pharm Bull 40: 2182-2184, 1992.
8. Miyamoto K, Wakabayashi D, Minamino T and Nomura M: Glutathione-S-transferase P-form dependent chlorambucil resistance in Yoshida rat ascites hepatoma cell lines. Cancer Lett 78. 77-83, 1994
9. Wang AL and Tew KD: Increased glutathione-S-transferase activity in a cell line with acquired resistance to nitrogen mustards. Cancer Treat Rep 69: 677-682, 1985
10. Cornwell MM, Gottesman MM and Patan I: Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells. J Biol Chem 261. 7921-7928, 1986.
11. Hamada H and Tsuruo T. Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance: 170- to 180-kilodalton membiane glycoprotein is an ATPase. J Biol Chem 263: 1454-1458, 1988.
12. Tew KD, Bomber AM and Hoffman SJ: Ethacrynic acid and piriprost as enhancers of cyctotoxicity in drug resistant and sensitive cell lines. Cancer Res 48: 3622-3625, 1988
13. Hagiwara M, Wakusawa S, Miyamoto K and Hidaka H: Obviation of drug resistance and affinity purification of P-glycoprotein by isoquinolinesulfonamides. Cancer Lett 60: 103-107, 1991.
14. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y: Increased accumulation of vincristine and Adriamycin in drug-resistant tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42: 4730-4733, 1982.
15. Tamai K, Satoh K, Tsuchida S, Hatayama I, Maki T and Sato K: Specific inactivation of glutathione S-transfer ase in class pi by SH-modifiers. Biochem Biophys Res Commun 67: 331-338, 1990.
16. Griffith OW and Meister A. Potent and specific inhibition of glutathione synthesis in buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 254: 7558-7560, 1979.
17. Deffie AM, Batra JK and Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 49: 58-62, 1989
18. Liu LF and Miller KG: Eukaryotic DNA topoisomerases; two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci USA 78: 3487-3491, 1981.
19. Kasahara K, Fujiwara Y and Sugimoto Y: Determination of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in a human lung cancer cell line. J Natl Cancer Inst 84. 113-118, 1992.
20. Onosaka S, Tanaka K, Doi M and Okahara K: A simplified procedure for determination of metallothionine in animal tissue. Eisei Kagaku 24: 128-131, 1978.
21. Kaneda N, Nagata H, Furuta T and Yokokura T: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715-1720, 1990.
22. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4191, 1991.
23. Gupta RS, Gupta R, Eng B, Lock RB, Ross WE, Hertzberg RP, Caranfa MJ and Johnson RK: Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form to topoisomerase I. Cancer Res 48. 6404-6410, 1988.
24. Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP and Johnson RK: Development of a stable CPT-resistant subline of P388 leukemia with reduced topoisomerase I content Mol Pharmacol 38: 471-480, 1990.
25. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF and Saijo N: Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human nonsmall cell lung cancer: Characterization and mechanism of resistance. Cancer Res 50: 5919-5924, 1990.
26. Chen AY, Yu C, Postmesil M, Wall ME, Wani MC and Liu LF: Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51: 6039-6044, 1991.